Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Pediatric Endocrinology · Classic Congenital Adrenal Hyperplasia

What Are Long-Term Side Effects of Steroids in CAH?

At a Glance

For children with CAH, lifelong hydrocortisone replaces missing cortisol and helps control excess androgens. Too much can cause weight gain, slower growth, high blood pressure, or bone problems, while too little can shorten adult height; ongoing monitoring helps find the safest dose.

It is completely natural to worry about the side effects of giving your child steroids every day. For a child with Classic Congenital Adrenal Hyperplasia (CAH), daily glucocorticoids (like hydrocortisone) serve two vital purposes: they replace the cortisol your child’s body cannot make, and they help reduce the overproduction of androgens (hormones that are normally present in everyone, but are elevated in CAH) [1][2].

Because of this dual purpose, the treatment is different from the high steroid doses used to suppress the immune system in conditions like asthma or arthritis. However, balancing androgen control against the risks of glucocorticoid excess is complex, and side effects remain a possibility that requires lifelong monitoring [3][4].

The Balancing Act: Finding the Lowest Effective Dose

The primary challenge in managing CAH is finding the lowest effective dose for your child’s specific needs—not too much, and not too little. Doctors often measure doses in mg/m²/day, which adjusts the amount of medication based on your child’s body size [1].

  • The Lowest Effective Dose: The goal is to provide just enough hydrocortisone to replace missing cortisol and keep androgens controlled, without giving more than necessary [5]. While many children do well and track normally on growth charts, risks cannot be entirely eliminated, and individual outcomes vary [6][3].
  • Overtreatment (Too Much): If a child is consistently given a dose higher than their body needs to control androgens, they are at risk for long-term complications [2]. Chronic overtreatment can lead to excessive weight gain, insulin resistance (which affects how the body processes blood sugar), and reduced growth velocity [2][7][8]. High cumulative doses can also increase the risk of lower bone density or osteoporosis in adulthood [9][10]. Additionally, excessive mineralocorticoid (fludrocortisone) treatment or excess body weight can contribute to high blood pressure [11][12].
  • Undertreatment (Too Little): Conversely, if the dose is too low, the adrenal glands will overproduce androgens. This can cause a child’s bones to mature too quickly—a condition known as advanced bone age. While this might make a child taller than their peers in the short term, their growth plates can close too early, resulting in a much shorter adult height [13][14].

Essential Safety: Never Stop Medication on Your Own

Because of the risks of weight gain or weak bones, some parents might be tempted to lower or stop their child’s steroid doses. Never change or stop your child’s medication without consulting your endocrinologist. Doing so can trigger a life-threatening adrenal crisis. Your family must have an individualized “sick-day” plan, which includes stress-dosing (giving extra glucocorticoids) during fever, significant illness, vomiting, or surgery. You should also be trained on how to use emergency injectable hydrocortisone if your child cannot keep oral medication down, and your child should wear medical-alert jewelry [15].

How Your Care Team Monitors Your Child

Because the ideal dose changes as your child grows, their endocrinologist will closely monitor their health to prevent both overtreatment and undertreatment. Strict reliance on a single blood test is not recommended; doctors must look at the big picture [4][16].

  • Routine Blood Tests: Your doctor will regularly check hormone markers like 17-OHP, androstenedione, and testosterone [17][18]. The goal is not to drive every result (especially 17-OHP) into the perfectly “normal” range, as trying to normalize 17-OHP often requires giving too much hydrocortisone, leading to overtreatment [19][16]. Electrolytes and renin (an enzyme that helps control blood pressure) are also checked to ensure the fludrocortisone dose is correct [12].
  • Growth and Clinical Checks: Tracking your child’s height, weight, BMI, and blood pressure over time is one of the most reliable ways to evaluate if their steroid dose is correct [20][4].
  • Bone Age X-rays: In children, X-rays of the left hand and wrist are used to estimate skeletal maturity. This does not measure bone strength, but rather tells the doctor how much growing time your child’s skeleton has left [21]. The frequency of these X-rays is highly individualized based on your child’s growth and pubertal signs [20][4].
  • DXA Scans: A Dual-Energy X-ray Absorptiometry (DXA) scan measures bone mineral density. DXA scans are not automatically required for every child. They are ordered according to specific risk factors, such as a history of fractures or prolonged periods of high-dose steroid use, and the results must be interpreted using age- and size-adjusted scores (Z-scores) [9][4].

Living with CAH means navigating a lifelong balancing act. By working closely with your care team, carefully monitoring growth and lab trends, and maintaining open communication, you can help manage the risks associated with lifelong steroid therapy.

Common questions in this guide

What long-term problems can steroid treatment cause in a child with CAH?
When the dose is higher than needed, a child may develop excessive weight gain, insulin resistance, slower growth, or lower bone density. Excess fludrocortisone or body weight can also contribute to high blood pressure. These effects are not inevitable, and the safest dose is individualized and monitored.
Can hydrocortisone change my child’s growth or adult height?
Too much hydrocortisone can slow growth. Too little can leave androgen levels high, causing bones to mature too quickly and growth plates to close early, which may reduce adult height even if a child grows faster at first. Endocrinologists use growth patterns and bone age to help adjust the dose.
How do doctors know whether my child’s CAH steroid dose is too high or too low?
They consider the dose relative to body size, hormone markers such as 17-OHP, androstenedione, and testosterone, along with height, weight, body mass index, blood pressure, and pubertal development. They look at trends and overall health rather than relying on one blood test. Trying to make every hormone result normal can lead to too much hydrocortisone.
Does my child need bone-age X-rays or a DXA scan while taking steroids?
A bone-age X-ray estimates how mature the bones are and how much growth time remains; it does not measure bone strength. A DXA scan measures bone mineral density and may be considered after factors such as fractures or prolonged high-dose steroid use. Not every child needs a DXA scan automatically, and results are interpreted using age- and size-adjusted scores.
What happens if we stop hydrocortisone to avoid side effects?
Do not lower or stop hydrocortisone or other prescribed CAH medicines without the endocrinologist’s advice, because missing replacement can cause a life-threatening adrenal crisis. Families need a sick-day plan for extra medicine during fever, serious illness, vomiting, or surgery, plus emergency injectable hydrocortisone if oral medicine cannot stay down. Medical-alert jewelry is also recommended.
How can we reduce the risks of lifelong steroid treatment?
Work with the endocrinology team to use the lowest dose that replaces missing cortisol and controls excess androgens. Keep medication timing consistent, record the last dose before blood tests, attend growth and blood pressure checks, and follow the sick-day plan. Do not change the dose on your own.

Related questions

Should CAH Genital Surgery Be Delayed or Done in Infancy? What Should I Do If My Child With CAH Vomits Hydrocortisone? When Should I Stress Dose My Child With CAH for an Illness? Are False Positive CAH Newborn Screens Common for Babies? Does Classic CAH Affect Female Fertility and Pregnancy?
Show more
How Is Salt-Wasting CAH Diagnosed vs Simple-Virilizing CAH? How Can I Cope With My Child's New Classic CAH Diagnosis? What Are TARTs in Classic CAH? How Are They Monitored? What Are the Chances of Another Baby With Classic CAH? What Are Signs of a Salt-Wasting Crisis in Infants With CAH? What Are Signs of Too Much or Too Little Steroid in CAH? What Is Crinecerfont and How Does It Treat Classic CAH? What Should Be in a CAH Emergency Kit for Your Child? Why Do Babies With Salt-Wasting CAH Need Sodium Supplements?

Get notified when new evidence is published on Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (21)
  1. 1

    Exogenous glucocorticoid dose impacts circulating microRNA expression in patients with adrenal insufficiency due to 21-hydroxylase deficiency.

    Kolli V, Trick J, Schulman A, et al.

    Frontiers in endocrinology 2026; (17()):1784619 doi:10.3389/fendo.2026.1784619.

    PMID: 41987891
  2. 2

    Current and future perspectives on clinical management of classic 21-hydroxylase deficiency.

    Yogi A, Kashimada K

    Endocrine journal 2023; (70(10)):945-957 doi:10.1507/endocrj.EJ23-0075.

    PMID: 37380491
  3. 3

    Long-term cardio-metabolic outcomes in patients with classical congenital adrenal hyperplasia: is the risk real?

    Gomes LG, Mendonca BB, Bachega TASS

    Current opinion in endocrinology, diabetes, and obesity 2020; (27(3)):155-161 doi:10.1097/MED.0000000000000545.

    PMID: 32304389
  4. 4

    Treatment and Follow-up of Congenital Adrenal Hyperplasia Due to 21-hydroxylase Deficiency in Childhood and Adolescence

    Peltek Kendirci HN, Ünal E, Dündar İ, et al.

    Journal of clinical research in pediatric endocrinology 2025; (17(Suppl 1)):12-22 doi:10.4274/jcrpe.galenos.2024.2024-6-26-S.

    PMID: 39713876
  5. 5

    Phase 3 Trial of Crinecerfont in Pediatric Congenital Adrenal Hyperplasia.

    Sarafoglou K, Kim MS, Lodish M, et al.

    The New England journal of medicine 2024; (391(6)):493-503 doi:10.1056/NEJMoa2404655.

    PMID: 38828945
  6. 6

    Clinical Variability in Congenital Adrenal Hyperplasia: A Distinct Subgroup with a Low Glucocorticoid Dose Requirement.

    Ustyol A, Eugster EA

    Hormone research in paediatrics 2026; (99(7)):977-981 doi:10.1159/000546883.

    PMID: 40550223
  7. 7

    Relationship between adipokines and androgens in children and young adults with congenital adrenal hyperplasia.

    Apsan J, Lekarev O, Thomas C, et al.

    Frontiers in endocrinology 2024; (15()):1433378 doi:10.3389/fendo.2024.1433378.

    PMID: 39175574
  8. 8

    The urinary steroidome of treated children with classic 21-hydroxylase deficiency.

    Kamrath C, Wettstaedt L, Boettcher C, et al.

    The Journal of steroid biochemistry and molecular biology 2017; (165(Pt B)):396-406 doi:10.1016/j.jsbmb.2016.08.006.

    PMID: 27544322
  9. 9

    Bone Mineral Density in Adults With Congenital Adrenal Hyperplasia: A Systematic Review and Meta-Analysis.

    Rangaswamaiah S, Gangathimmaiah V, Nordenstrom A, Falhammar H

    Frontiers in endocrinology 2020; (11()):493 doi:10.3389/fendo.2020.00493.

    PMID: 32903805
  10. 10

    Challenges in Adolescent and Adult Males With Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency.

    Claahsen-van der Grinten HL, Adriaansen BPH, Falhammar H

    The Journal of clinical endocrinology and metabolism 2025; (110(Supplement_1)):S25-S36 doi:10.1210/clinem/dgae718.

    PMID: 39836620
  11. 11

    Blood Pressure in a Large Cohort of Children and Adolescents With Classic Adrenal Hyperplasia (CAH) Due to 21-Hydroxylase Deficiency.

    Bonfig W, Roehl FW, Riedl S, et al.

    American journal of hypertension 2016; (29(2)):266-72 doi:10.1093/ajh/hpv087.

    PMID: 26071487
  12. 12

    The role of renin, fludrocortisone, and hypertension in early childhood in patients with congenital adrenal hyperplasia.

    Chin X, van der Meijden JC, van Herwaarden AE, Claahsen-van der Grinten HL

    European journal of endocrinology 2026; (195(2)):271-280 doi:10.1093/ejendo/lvag146.

    PMID: 42554593
  13. 13

    Growth curves for congenital adrenal hyperplasia from a national retrospective cohort.

    Bretones P, Riche B, Pichot E, et al.

    Journal of pediatric endocrinology & metabolism : JPEM 2016; (29(12)):1379-1388.

    PMID: 27852974
  14. 14

    Characteristics of Growth in Children With Classic Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency During Adrenarche and Beyond.

    Troger T, Sommer G, Lang-Muritano M, et al.

    The Journal of clinical endocrinology and metabolism 2022; (107(2)):e487-e499 doi:10.1210/clinem/dgab701.

    PMID: 34599587
  15. 15

    Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline.

    Speiser PW, Arlt W, Auchus RJ, et al.

    The Journal of clinical endocrinology and metabolism 2018; (103(11)):4043-4088 doi:10.1210/jc.2018-01865.

    PMID: 30272171
  16. 16

    Salivary 17-Hydroxyprogesterone Levels in Children with Congenital Adrenal Hyperplasia: A Retrospective Longitudinal Study Considering Auxological Parameters.

    Dubinski I, Bechtold S, Bidlingmaier M, et al.

    Hormone research in paediatrics 2023; (96(3)):259-266 doi:10.1159/000526485.

    PMID: 35960318
  17. 17

    Current insights into monitoring of congenital adrenal hyperplasia.

    Leusink QM, Verploegen EEW, Adriaansen BPH, et al.

    Frontiers in endocrinology 2026; (17()):1774145 doi:10.3389/fendo.2026.1774145.

    PMID: 41767372
  18. 18

    Biomarkers in congenital adrenal hyperplasia.

    Bacila IA, Lawrence NR, Badrinath SG, et al.

    Clinical endocrinology 2024; (101(4)):300-310 doi:10.1111/cen.14960.

    PMID: 37608608
  19. 19

    Congenital adrenal hyperplasia: New biomarkers and adult treatments.

    Dreves B, Reznik Y, Tabarin A

    Annales d'endocrinologie 2023; (84(4)):472-480 doi:10.1016/j.ando.2023.01.008.

    PMID: 36842612
  20. 20

    Monitoring treatment in pediatric patients with 21-hydroxylase deficiency.

    Itonaga T, Hasegawa Y

    Frontiers in endocrinology 2023; (14()):1102741 doi:10.3389/fendo.2023.1102741.

    PMID: 36843618
  21. 21

    Clinical tools for evaluating congenital adrenal hyperplasia in resource-limited hospitals: a study at a tertiary hospital in Saudi Arabia.

    Alhazmi D, Alabdulqader A, Almeqbel S, et al.

    Frontiers in endocrinology 2026; (17()):1730774 doi:10.3389/fendo.2026.1730774.

    PMID: 41727684

This page is for informational purposes only and does not constitute medical advice about your child’s CAH treatment. Do not change or stop hydrocortisone or fludrocortisone without guidance from your child’s endocrinology team.